Research Analysts Set Expectations for Aura Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:AURA)

Aura Biosciences, Inc. (NASDAQ:AURA) – Lifesci Capital issued their Q3 2024 earnings estimates for shares of Aura Biosciences in a research note issued on Monday, September 9th. Lifesci Capital analyst A. Dhankher expects that the company will post earnings of ($0.42) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.71) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.65) EPS and FY2025 earnings at ($2.52) EPS.

Several other analysts have also commented on the company. HC Wainwright initiated coverage on Aura Biosciences in a report on Thursday, July 25th. They issued a “buy” rating and a $21.00 price objective on the stock. JMP Securities reissued a “market outperform” rating and issued a $19.00 price target on shares of Aura Biosciences in a research note on Wednesday, August 28th.

Aura Biosciences Stock Up 0.6 %

Shares of Aura Biosciences stock opened at $9.07 on Thursday. The firm has a market cap of $449.36 million, a PE ratio of -4.88 and a beta of 0.36. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.35. The business has a 50-day moving average price of $8.36 and a 200 day moving average price of $7.85.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AURA. American Century Companies Inc. purchased a new stake in shares of Aura Biosciences during the second quarter worth $119,000. American International Group Inc. grew its stake in Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new stake in Aura Biosciences in the 1st quarter valued at about $144,000. Trexquant Investment LP lifted its stake in Aura Biosciences by 64.5% in the 4th quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after purchasing an additional 6,809 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after purchasing an additional 18,011 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.